LIVAZEBE
LIVE

Serial Number

79399425

Owner

KOWA COMPANY LTD.

Filing Date

May 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

LIVAZEBE Trademark

Serial Number: 79399425 • Registration: 7617325

LIVAZEBE is a trademark filed by KOWA COMPANY LTD. on May 31, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

KOWA COMPANY LTD. (420 trademarks)

NO. 4-14 CHOME
TOKYO 103 , JP

Entity Type: 03

Trademark Details

Filing Date

May 31, 2024

Registration Date

December 24, 2024

Published for Opposition

November 5, 2024

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; veterinary preparations, namely, veterinary preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, veterinary preparations for treatment of fatty liver and steatohepatitis, veterinary preparations for the treatment of cardiovascular disorders and metabolic disorders, veterinary preparations for the treatment of digestive system disease, veterinary preparations for the treatment of primary biliary cirrhosis, veterinary preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, veterinary preparations for the treatment of liver disease, veterinary preparations for the treatment of metabolic disease, veterinary preparations for the prevention and treatment of disorders of the metabolic system, analgesics; veterinary pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; veterinary pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; sanitary preparations for medical use; anti-inflammatory agents, namely, topical preparations in the form of gels and salves, adhesive skin patches, liquid formulations, cream and sprays, all for relieving pain.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 18, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 3, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 23, 2025 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2024 R.PR
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTICE OF PUBLICATION
Oct 16, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 24, 2024 CNSA
ASSIGNED TO EXAMINER
Sep 16, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 12, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 9, 2024 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jul 5, 2024 SDRC